Posted by Michael Wonder on 25 Jun 2024
Tagrisso with the addition of chemotherapy approved in Japan as new first-line treatment for patients with EGFR mutated advanced lung cancer
25 June 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months versus standard of care.
AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in Japan for the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
